Cessatech - Ventis Pharma US partnership - Q&A
On 30 June – Cessatech A/S (“Cessatech” or “the Company”) releases a short Question and Answers (Q&A) overview, based all the positive feedback and questions from the exclusive US license and collaboration agreement with Ventis Pharma.Selected top 10 investor questions 1. What is the expected revenue for 2024? A: Revenue guidance will be provided once we have seen the early progression of the launch – but we expect a significant amount 2. Could you explain the $200-400M market opportunity? A: Ventis Pharma expects this ‘combined’ opportunity to be both the ‘early access